Ipriflavone
OTHER NAME(S): 7-Isopropoxy-Isoflavone, 7-Isopropoxy Isoflavone, FL-113, TC-80, 7-isopropoxyisoflavone, Ipriflavona
Overview
Ipriflavone is made in the laboratory from a compound found in the soy plant. In some countries, ipriflavone is available as a prescription. In the United States, ipriflavone is considered a dietary supplement.
Ipriflavone is used for weak and brittle bones (osteoporosis) and for a bone disease that causes pain (Paget disease). Ipriflavone is also used by bodybuilders, but there is no good scientific evidence to support this use.
Ipriflavone can block part of the process that leads to bone loss.
Ipriflavone can block part of the process that leads to bone loss.
Uses
Likely Effective for
- Weak and brittle bones (osteoporosis). Taking ipriflavone with calcium daily can prevent bone loss in postmenopausal women with osteoporosis. There is some evidence that it might actually increase bone strength in some of these women, and it also seems to decrease pain from osteoporosis. Taking ipriflavone with estrogen also seems to prevent osteoporosis and increase bone strength in older women. Adding calcium might make this combination work even better.
Possibly Effective for
- A bone disease that can cause pain (Paget disease). Early research shows that taking ipriflavone might decrease bone pain in some people with Paget disease.
Insufficient Evidence for
- A bone disorder that occurs in people with kidney disease (renal osteodystrophy).
- Food allergies.
- Increasing metabolism in bodybuilders.
- Stroke.
- Other conditions.
More evidence is needed to rate the effectiveness of ipriflavone for these uses.
Side Effects
When taken by mouth: Ipriflavone is LIKELY SAFE for most people when used with proper medical supervision. There is concern that ipriflavone can cause a decreased white blood cell count (lymphocytopenia) in people taking it for greater than six months.
Precautions
When taken by mouth: Ipriflavone is LIKELY SAFE for most people when used with proper medical supervision. There is concern that ipriflavone can cause a decreased white blood cell count (lymphocytopenia) in people taking it for greater than six months.
Pregnancy and breast-feeding: There isn't enough reliable information to know if ipriflavone is safe to use when pregnant or breast-feeding. Stay on the safe side and avoid use.
Weak immune system: Ipriflavone can lower the body's white blood cell count, making it more difficult for the body to fight off infection. This is especially concerning in people who already have a weak immune system due to AIDS, drugs used to prevent organ rejection after transplant, chemotherapy, or other causes. If you have a weak immune system, check with your healthcare provider before starting ipriflavone.
Interactions
Moderate Interaction
Be cautious with this combination
- Medications changed by the liver (Cytochrome P450 1A2 (CYP1A2) substrates) interacts with IpriflavoneSome medications are changed and broken down by the liver. Ipriflavone might decrease how quickly the liver breaks down some medications. Taking ipriflavone along with some medications that are changed by the liver might increase the effects and side effects of some medications. Before taking ipriflavone, talk to your healthcare provider if you take any medications that are changed by the liver. Some of these medications that are changed by the liver include clozapine (Clozaril), cyclobenzaprine (Flexeril), fluvoxamine (Luvox), haloperidol (Haldol), imipramine (Tofranil), mexiletine (Mexitil), olanzapine (Zyprexa), pentazocine (Talwin), propranolol (Inderal), tacrine (Cognex), theophylline, zileuton (Zyflo), zolmitriptan (Zomig), and others.
- Medications changed by the liver (Cytochrome P450 2C9 (CYP2C9) substrates) interacts with IpriflavoneSome medications are changed and broken down by the liver. Ipriflavone might decrease how quickly the liver breaks down some medications. Taking ipriflavone along with some medications that are broken down by the liver can increase the effects and side effects of some medications. Before taking ipriflavone, talk to your healthcare provider if you take any medications that are changed by the liver. Some medications that are changed by the liver include amitriptyline (Elavil), diazepam (Valium), zileuton (Zyflo), celecoxib (Celebrex), diclofenac (Voltaren), fluvastatin (Lescol), glipizide (Glucotrol), ibuprofen (Advil, Motrin), irbesartan (Avapro), losartan (Cozaar), phenytoin (Dilantin), piroxicam (Feldene), tamoxifen (Nolvadex), tolbutamide (Tolinase), torsemide (Demadex), warfarin (Coumadin), and others.
- Medications that decrease the immune system (Immunosuppressants) interacts with IpriflavoneIpriflavone might decrease the immune system. Taking ipriflavone along with other medications that decrease the immune system might decrease the immune system too much. Avoid taking ipriflavone with medications that decrease the immune system. Some medications that decrease the immune system include azathioprine (Imuran), basiliximab (Simulect), cyclosporine (Neoral, Sandimmune), daclizumab (Zenapax), muromonab-CD3 (OKT3, Orthoclone OKT3), mycophenolate (CellCept), tacrolimus (FK506, Prograf), sirolimus (Rapamune), prednisone (Deltasone, Orasone), corticosteroids (glucocorticoids), and others.
- Theophylline interacts with IpriflavoneThe body breaks down theophylline to get rid of it. Ipriflavone might decrease how quickly the body gets rid of theophylline. Taking ipriflavone along with theophylline might increase the effects and side effects of theophylline.
Dosing
BY MOUTH:
- For weak and brittle bones (osteoporosis): 200 mg of ipriflavone three times daily.
- For a bone disease that can cause pain (Paget disease): 600-1200 mg of ipriflavone daily.
References
- Arjmandi BH, Birnbaum RS, Juma S, et al. The synthetic phytoestrogen, ipriflavone, and estrogen prevent bone loss by different mechanisms. Calcif Tissue Int 2000;66:61-5.
- Melis GB, Paoletti AM, Bartolini R, et al. Ipriflavone and low doses of estrogens in the prevention of bone mineral loss in climacterium. Bone Miner 1992;19,Suppl 1:S49-56.
- Agnusdei D, Adami S, Cervetti R, et al. Effects of ipriflavone on bone mass and calcium metabolism in postmenopausal osteoporosis. Bone Miner 1992;19,Suppl 1:S43-8.
- Ohta H, Komukai S, Makita K, et al. Effects of 1-year ipriflavone treatment on lumbar bone mineral density and bone metabolic markers in postmenopausal women with low bone mass. Horm Res 1999;51:178-83.
- Head KA. Ipriflavone: an important bone-building isoflavone. Altern Med Rev 1999;4:10-22.
- Agnusdei D, Bufalino L. Efficacy of ipriflavone in established osteoporosis and long-term safety. Calcif Tissue Int 1997;61,Suppl 1:S23-7.
- Gennari C, Adami S, Agnusdei D, et al. Effect of chronic treatment with ipriflavone in postmenopausal women with low bone mass. Calcif Tissue Int 1997;61,Suppl 1:S19-22.
- Petilli M, Fiorelli G, Benvenuti S, et al. Interactions between ipriflavone and the estrogen receptor. Calcif Tissue Int 1995;56:160-5.
- Alexandersen P, Toussaint A, Christiansen C, et al. Ipriflavone in the treatment of postmenopausal osteoporosis: A randomized controlled trial. JAMA 2001;285:1482-8.
- Gennari C, Agnusdei D, Crepaldi G, et al. Effect of ipriflavone-a synthetic derivative of natural isoflavones-on bone mass loss in the early years after menopause. Menopause 1998;5:9-15.
- Agnusdei D, Crepaldi G, Isaia G, et al. A double blind, placebo-controlled trial of ipriflavone for prevention of postmenopausal spinal bone loss. Calcif Tissue Int 1997;61:142-7.
- Gambacciani M, Ciaponi M, Cappagli B, et al. Effects of combined low dose of the isoflavone derivative ipriflavone and estrogen replacement on bone mineral density and metabolism in postmenopausal women. Maturitas 1997;28:75-81.
- Agnusdei D, Gennari C, Bufalino L. Prevention of early postmenopausal bone loss using low doses of conjugated estrogens and the non-hormonal, bone-active drug ipriflavone. Osteoporos Int 1995;5:462-6.
- Valente M, Bufalino L, Castiglione GN, et al. Effects of 1-year treatment with ipriflavone on bone in postmenopausal women with low bone mass. Calcif Tissue Int 1994;54:377-80.
- Ushiroyama T, Okamura S, Ikeda A, et al. Efficacy of ipriflavone and 1 alpha vitamin D therapy for the cessation of vertebral bone loss. Int J Gynaecol Obstet 1995;48:283-8.
- Agnusdei D, Zacchei F, Bigazzi S, et al. Metabolic and clinical effects of ipriflavone in established post-menopausal osteoporosis. Drugs Exp Clin Res 1989;15:97-104.
- Agnusdei D, Camporeale A, Gonnelli S, et al. Short-term treatment of Paget's disease of bone with ipriflavone. Bone Miner 1992;19 Suppl 1:S35-42.
- Hyodo T, Ono K, Koumi T, et al. A study of the effects of ipriflavone administration on hemodialysis patients with renal osteodystrophy: preliminary report. Nephron 1991;58:114-5.
- Monostory K, Vereczkey L, Levai F, et al. Ipriflavone as an inhibitor of human cytochrome P450 enzymes. Br J Pharmacol 1998;123:605-10.
- Melis GB, Paoletti AM, Cagnacci A, et al. Lack of any estrogenic effect of ipriflavone in postmenopausal women. J Endocrinol Invest 1992;15:755-61.
- Gambacciani M, Cappagli B, Piaggesi L, et al. Ipriflavone prevents the loss of bone mass in pharmacological menopause induced by GnRH-agonists. Calcif Tissue Int 1997;61:S15-8.
- Nozaki M, Hashimoto K, Inoue Y, et al. Treatment of bone loss in oophorectomized women with a combination of ipriflavone and conjugated equine estrogen. Int J Gynaecol Obstet 1998;62:69-75.
- Maugeri D, Panebianco P, Russo MS, et al. Ipriflavone-treatment of senile osteoporosis: results of a multicenter, double-blind clinical trial of 2 years. Arch Gerontol Geriatr 1994;19:253-63.
- Scali G, Mansanti P, Zurlo A, et al. Analgesic effect of ipriflavone versus Calcitonin in the treatment of osteoporotic vertebral pain. Curr Ther Res 1991;49:1004-10.
- Takahashi J, Kawakatsu K, Wakayama T, Sawaoka H. Elevation of serum theophylline levels by ipriflavone in a patient with chronic obstructive pulmonary disease. Eur J Clin Pharmacol 1992;43:207-8.
- Somekawa Y, Chiguchi M, Ishibashi T, et al. Efficacy of ipriflavone in preventing adverse effects of leuprolide. J Clin Endocrinol Metab 2001;86:3202-6..
- Masilamani M, Chang LM, Kamalakannan M, et al. Dietary isoflavone supplementation for food allergy: A pilot study. J Allergy Clin Immunol Pract. 2017;5(6):1760-2.e4. doi: 10.1016/j.jaip.2017.04.005.
- Hu Q, Long C, Wu D, et al. The efficacy and safety of ipriflavone in postmenopausal women with osteopenia or osteoporosis: A systematic review and meta-analysis. Pharmacol Res. 2020;159:104860.
- Nie R, Lu J, Xu R, et al. Ipriflavone as a non-steroidal glucocorticoid receptor antagonist ameliorates diabetic cognitive impairment in mice. Aging Cell 2022;21(3):e13572.